A CD19-targeted allogeneic product was shown to be safe and efficacious in heavily pre-treated adult patients with relapsed and refractory B-ALL with allogeneic off-the-shelf UCART19 cells in the clinical trial [CALM] (NCT02746952) (21). The gene discussed is CD19; the disease is acute lymphoblastic leukemia.